Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2001 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

Analysts fell to the sidelines weighing in on Anavex Life Sciences (AVXL – Research Report), IO Biotech (IOBT – Research Report) and Theriva Biolog...

Analysts Are Neutral on Top Healthcare Stocks: Anavex Life Sciences (AVXL), IO Biotech (IOBT)

Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday.


Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, Anavex Life Sciences announced that the Committee for Medicinal Produc...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVXL	$3.31	+4.26%	1.94M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVXL	$3.31	+4.3%	1.94M
3
4
5
6

AVXL

AVXL

No Data Available

Get Anavex Life Sciences Corp. Data in Excel

Get Anavex Life Sciences Corp. Data in Excel